<< Back to News

System Formulary Update
Ophthalmic Corticosteroid Implant and Injection

Situation:

The ophthalmic corticosteroid implant and injection class review was approved by the System Pharmacy and Therapeutics Committee meeting in December 2024. 

Background:

The following medication was reviewed: dexamethasone (Ozurdex) intravitreal implant, dexamethasone (Dextenza) intracanalicular insert, dexamethasone (Dexycu) intraocular suspension, fluocinolone (Yutiq) intravitreal implant, fluocinolone (Retisert) intravitreal implant, fluocinolone (Iluvien) intravitreal implant, triamcinolone (Xipere) intraocular suspension, triamcinolone (Triesence) intraocular suspension

Assessment/Recommendation:

System P&T voted to include the following products on the UNC Health Medication Formulary:

• Dexamethasone (Ozurdex) 0.7 mg intravitreal implant [ERX 99461]
• Dexamethasone (Dextenza) 0.4 mg intracanalicular insert [ERX 186611]
• Fluocinolone (Yutiq) 0.18 mg intravitreal implant [ERX 186141]
• Triamcinolone (Triesence) 40 mg/mL intraocular suspension [ERX 89128]
• Triamcinolone (Xipere) 40 mg/mL suprachoroidal suspension [ERX 194385]

System P&T voted to remove the following products on the UNC Health Medication Formulary:

• Flucinolone (Retisert) intravitreal implant

Note: Stock of this formulary product may vary at individual entities 

Formulary/Epic Changes will Go-Live on Tuesday, February 25, 2025